Full Length Review Article

Periodontal Vaccine – A Review

Dr. Shiva Manjunath, R. G., *Dr. Arijit Sarkar, Dr. Deepak Singla, Dr. Akansha Singh, Dr. Subhango Chatterjee and Dr. Neeraj Chandra

Department of Periodontics and Implantology, I.D.S. Bareilly, U.P. India

Accepted 19th June 2015; Published Online 31st July 2015

ABSTRACT

Vaccination is a process that induces specific immune resistance to a bacterial or viral infection. Edward Jenner developed and established the principle of vaccination using the cross protection conferred by cowpox virus, which is non-pathogenic in humans. With the rapid growth of microbial genome sequencing and bioinformatics analysis tools we have the potential to examine all the genes and proteins from any human pathogen. This technique has the capability to provide us with new targets for anti-microbial drugs and vaccines. However, to realize this potential new bioinformatics and experimental approaches to select these targets from the myriad of available candidates are required.

Key words: Vaccination Genome Sequence, Bio-informatics.

INTRODUCTION

Periodontal diseases belong to a heterogeneous family of diseases, which demands a clear need for a better understanding of the etiology and pathogenesis behind formulation of a vaccine against the same. Both specific and nonspecific plaque hypothesis has its own merits and demerits (Loesche, 1976 and 1988). Extensive research has been conducted to determine the role of cell-mediated immunity and serum antibodies in protection against infectious agents, less is known about the role of mucosal immunity (Journal clinical microbiology review, 1992). Vaccination is a process that induces specific immune resistance to a bacterial or viral infection.

Specific immune response

Chronic inflammation, if protracted, can result in an adaptation called the specific immune response. The specific immune response requires lymphocytes that use two types of receptors to generate specific immune responses, the b-cell antigen receptor and the t- cell antigen receptor.

Four phases are involved in the generation of specific immunity: (Loesche, 1988)

- Clonal selection – Selection of lymphocytes that bear receptors recognizing the specific antigen
- Clonal expansion – Proliferation of those lymphocytes
- Clonal contraction – Death of effector lymphocytes
- Memory – Maintenance of an expanded clone of cells that bear the specific receptors recognizing the antigen.

“Vaccination is the development of immunity or resistance to infection, after a secondary response (booster) that is adequate to consider the individual immune to a subsequent infection.”

Types of vaccination

Active immunization (Journal clinical microbiology review, 1992): Here, an individual immune system is stimulated by administrating killed or live attenuated products derived from micro-organisms. Passive immunization [Figure 1]: Here, the antibodies formed in one individual are transferred to another. DNA vaccination [Figure 2]: Here, DNA plasmids encoding genes required for antigen production are transferred to an individual.

Characteristics of an effective vaccine

- Safety
- Protectivity
- The ability to provide sustained protection
- The ability to produce neutralizing antibodies
- Stimulation of protective t-cells. Practical considerations like
- Cost-effectiveness
- Biological stability
- Access
- Minimum contraindications and side effects

Pathogenesis of periodontitis

Periodontitis is a disease of multi factorial origin with interaction among host, micro-organisms and environmental factors which includes genetic factors as well. Over 300 species of micro-organisms have been found to colonize the...
periodontal tissues, of which the following are considered to be the primary pathogens causing periodontitis (Immunization in Periodontics, 7; Verma et al., 1992; Kudyar et al., 2011)

- Porphyromonas gingivalis
- Aggregatibacter actinomycetemcomitans
- Tannerella forsythensis

These bacteria produce an array of antigens that stimulate pro-inflammatory cells and leads to the production of a wide variety of cytokines. These antigens may stimulate Th1 or Th2 cells. Antigens are taken up by dendritic cells and presented to CD-8 or CD-4 cells along with MHC antigens (McArthur et al., 1989).

CD-8 cells → Th 1 response → CMI → Pro inflammatory CD-4 cells → Th 2 response → Ab response → Protective

The host produces anti-bacterial substances such as defensins, cathelicidins and saposins, which protect the host tissues from bacterial products and forms the first line of defense. However, sometimes these are inactivated by the bacterial virulence factors. Once bacteria break this barrier, cytokines are produced, which can be both proinflammatory and anti-inflammatory. Production of inappropriate cytokines results in periodontitis (McArthur et al., 1989).

**History of periodontal vaccines**

From the time of Edward Jenner’s discovery of small pox vaccine in 1796, antigens of infectious pathogenic bacteria and viruses have been the targets for a variety of vaccines against a number of infectious diseases. Thus, most vaccines target one or multiple antigenic components of mono infecting bacteria or viruses. The principle of vaccination is based on two key elements of adaptive immunity namely specificity and memory (Journal of clinical microbiology review, 1992). Three periodontal vaccines were employed 1870. Locus Pasteur creates 1st Live att. Bacterial vaccine (chicpenchoecra) 1885. Pasteur creates the first Live attenuated viral vaccine (rabies), 1886 Typhoid, 1900 Cholera, 1992 Hepatitis, 1999 Meningococcus C Conjugate, 2004 DTa/ IPV/ Hib/ Ta/ IPV, 2006 (Combine Hib) (Kudyar, et al., Periodontal vaccine).

**Mechanism of action**

Types of periodontal immunization.

**Active immunization**

- Whole bacterial cells
- Sub unit vaccines
- Synthetic peptides as antigens

**Passive immunization**

- Murine monoclonal antibodies
- Plantibodies

**Genetic immunization**

- Plasmid vaccines
- Live, viral vector vaccines

**Active immunization**

Here, the entire cell with its components is inoculated into a host to bring about active immunization.

- Klausen; 1991 (Persson et al., 1994) have shown that levels of serum antibody to both whole cells and partially purified fimbriae from P. gingivalis were elevated in rats immunized with P. gingivalis cells and that the activities of collagenase and cysteine proteases in gingival and periodontal tissues were decreased.
- Kesavalu; 1992 (Page, 1982) observed protection against invasion, but no colonization against P. gingivalis in a mouse chamber model by immunization with either killed heterologous invasive or non-invasive P. gingivalis strains. The immunoresponse to whole cells or selected envelope component did not completely abrogate lesions, but eliminated mortality.

**Passive immunization**

Passive immunization is short lived, because the host does not respond to the immunization and protection lasts only as long as the injected antibody persists. Here, the antigens are injected into a vector that produces antibodies. These antibodies, when inoculated into a host, bring about passive immunization. Passive immunization can be brought about in two ways:

- Murine monoclonal antibodies
- Plantibodies

**Genetic immunization**

By the early 1990’s, scientists had begun to study new approaches for the production of vaccines that differ in structure from traditional ones. The strategy involves genetic engineering or recombinant DNA technology. There are two types:

- Plasmid vaccines
- Live, viral vector vaccines

**Preparations of human Periodontal Vaccine**

Three types of vaccines were employed for the control of periodontal diseases (Malhotra et al., 2011). These include the vaccines prepared from:

- Pure cultures of streptococci and other oral organisms
- Autogenous vaccines, which are prepared from dental plaque samples of patients with destructive periodontal diseases. Plaque samples are removed from the diseased site and are sterilized by heat or by immersion in iodine/formalin and are re-injected into the same patient, either locally or systemically.
- Stock vaccines such as Van Cott’s vaccine, Goldenberg’s vaccine, or Inava Endocorps vaccine.

**Components of periodontal bacteria tested for antigenicity and potential as vaccine candidates**

<table>
<thead>
<tr>
<th>Generic name</th>
<th>Species name</th>
<th>Antigenic components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Porphyromonas</td>
<td>Intermedia</td>
<td>Whole cell non invasive</td>
</tr>
<tr>
<td>P. gingivalis</td>
<td>Macaca</td>
<td>Whole cell</td>
</tr>
<tr>
<td>T. denticola</td>
<td>Nucleotum</td>
<td>Whole cell ATCC 35404</td>
</tr>
<tr>
<td>F. nucleatum</td>
<td>Actinomyce</td>
<td>Formalized whole cell</td>
</tr>
<tr>
<td>A. viscosus</td>
<td></td>
<td>Fimbrialadhesins of T14V</td>
</tr>
</tbody>
</table>
Limitations of periodontal vaccines

However, several issues should be addressed pertinent to the development of a sophisticated vaccine against human periodontitis. Firstly, human periodontal disease is multifactorial caused by manifold pathogens. The intricacy of the periodontopathic bacteria might be a problem as a substantial number of bacteria appears to be involved in periodontal disease. The multiplicity of pathogenic organisms indicates that vaccine design against periodontitis is very complex. Secondly, bacterial whole cells or crude extracts preparation for vaccination is not desirable because the antigenic determinants of bacteria potentially possess a high risk of cross-reactivity with human counterparts.

Some more serious complication may stem from the vaccinee from the patient. Vaccines may be contaminated with unwanted proteins or toxins, or even live viruses. Supposedly killed vaccines may not have been properly killed; attenuated vaccines may revert to the wild type (Journal clinical microbiology review, 1992). The patient maybe hypersensitive to minute amounts of contaminating proteins, or immune compromised, in which case any living vaccine is usually contraindicated. Furthermore, importantly, animal models for vaccine trials may pose inconsistencies with human models in majorhistocompatibility complex restriction of antigens presented by antigen presenting, thus obscuring the immunodominant epitope(s). A humanized mouse system has been projected that has been reconstituted with human peripheral blood lymphocytes. This system needs to meet the requirement of least leakiness of a mouse immune system. More recently, a genetically engineered mouse system, such as the non obese diabetes Non obese diabetic mouse CB 17-colony of BALB (mouse strain used in the study) prkdcscid/J mouse, has been initiated into the study of infectious and autoimmune diseases in humans. This model may also prove to be available tool for the study of periodontal disease and putative periodontal vaccines (Loesche, 1976).

As an innovative strategy, vaccines using cross reactive immunodominant epitopes as antigenic molecules in an attempt to stimulate antigen specific regulatory T cells (Tregs, CD4+, CD25+, FoxP3+), secreting IL 10 and Transforming growth factor β, may provide new clues for periodontal disease prevention, through the induction of either immune tolerance or an effector function. Periodontal disease as a multi factorial and poly microbial disease requires a sophisticated vaccine design regimen targeting multiple pathogenic species. Vaccine regimens including the commonly shared antigens by selected periodontopathogenic species would be considered an innovative strategy. Traditional periodontal vaccine trials aim to stimulate the immune system to produce increased levels of immunoglobulin of desired specificity. To accomplish this end, a conjugate vaccine (i.e. protein-CPS conjugate), dendritic-cell based immunotherapy, and subunit DNA vaccine encoding the desired immunogenic epitope have been devised.

Future of periodontal vaccine

As yet, there are no periodontal vaccine trials that have been successful in satisfying all requirements; to prevent the colonization of multiple pathogen bio film in the sub gingival area, to elicit a high level of effector molecules such as immunoglobulin sufficient to opsonize and phagocytose the invading organisms, to suppress alveolar bone loss, and to stimulate helper T-cell polarization that exerts cytokine functions optimal for protection against bacteria and tissue destruction. As an innovative strategy, vaccines using cross-reactive immunodominant epitopes as antigenic molecules in an attempt to stimulate antigen-specific regulatory T-cells (Tregs, CD4+, CD25+, FoxP3+), secreting IL-10 and TGF-β, may provide new clues for periodontal disease prevention, through the induction of either immune tolerance or an effector function. Periodontal disease as a multi factoral and poly microbial disease requires a sophisticated vaccine design regimen targeting multiple pathogenic species. Vaccine regimens including the commonly shared antigens by selected periodontopathogenic species would be considered an innovative strategy. Traditional periodontal vaccine trials aim to stimulate the immune system to produce increased levels of immunoglobulin of desired specificity. To accomplish this end, a conjugate vaccine (i.e. protein-CPS conjugate), dendritic-cell based immunotherapy, and subunit DNA vaccine encoding the desired immunogenic epitope have been devised.
Animal models for vaccine trials may pose discrepancies with human models in major histocompatibility complex-restriction of antigens presented by antigen presenting, thus obscuring the immunodominant epitope(s). A humanized mouse system has been proposed that has been reconstituted with human PBLs. This system needs to meet the requirement of least leakiness of a mouse immune system. More recently, a genetically engineered mouse system, such as the NOD.CB17 scid/scid mouse, has been introduced for the study of infectious and autoimmune diseases in humans. This model may also prove useful for the study of periodontal disease and putative periodontal vaccines.

Conclusion

The current treatment of periodontitis is nonspecific and is centered on the removal of plaque by mechanical debridement, often involving surgical procedures. This ongoing therapy is costly, painful and has a variable prognosis due in part to poor patient compliance. The use of antibiotics is limited by the need for constant treatment to prevent re-establishment of the pathogen. The elucidation of specific bacterial etiology suggests that the development of a specific treatment modality to target site colonization is now a rational approach to treat the disease. Vaccination may be an important adjunctive therapy to mechanical debridement in near future. It’s not a myth but a reality which will come true in the near future if research is carried out in right way in right direction.

REFERENCES


Herminajeng, E., Asmara, W., Yuswanto, A., Barid, I., Sosroseno, W.2002. Protective humoral immunity induced by surface-associated material from Actinobacillus actinomycetemcomitans in mice.


